Literature DB >> 8197319

Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center.

R K Heaton1, R A Velin, J A McCutchan, S J Gulevich, J H Atkinson, M R Wallace, H P Godfrey, D A Kirson, I Grant.   

Abstract

Individuals infected with the human immunodeficiency virus-Type 1 (HIV-1), are at increased risk for neurobehavioral impairment, particularly in later stages of the disease. Even patients in the medically asymptomatic or minimally symptomatic stages of infection may show mild deficits on comprehensive neuropsychological (NP) test batteries, although the clinical significance of such deficits remains uncertain. The present study used vocational difficulties as markers of clinical significance of NP impairment. In a sample of 289 HIV-infected, nondemented men, those who evidenced NP impairment had a higher unemployment rate (p < .001) than did their unimpaired counterparts. In HIV-positive subjects who remained employed, NP impairment was strongly associated with subjective decreases in job-related abilities. Neither depression nor medical symptoms could explain the relationship between the NP impairment and employment problems. These results are consistent with previous studies investigating other neuropsychiatric disorders, which suggest that even mild NP impairment can interfere with employment status. From this standpoint, such impairment in HIV-infected persons may be described as "clinically significant."

Entities:  

Mesh:

Year:  1994        PMID: 8197319     DOI: 10.1097/00006842-199401000-00001

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  61 in total

1.  Performance-based measures of everyday function in mild cognitive impairment.

Authors:  Terry E Goldberg; Jeremy Koppel; Lynda Keehlisen; Erica Christen; Ute Dreses-Werringloer; Concepcion Conejero-Goldberg; Marc L Gordon; Peter Davies
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

2.  Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS.

Authors:  Susanne May; Scott Letendre; Richard Haubrich; J Allen McCutchan; Robert Heaton; Edmund Capparelli; Ronald Ellis
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-10       Impact factor: 4.147

Review 3.  Neurocognitive impact of antiretroviral treatment: thinking long-term.

Authors:  Megan E McPhail; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

4.  Functional disability in medication management and driving among individuals with HIV: a 1-year follow-up study.

Authors:  April D Thames; Alyssa Arentoft; Monica Rivera-Mindt; Charles H Hinkin
Journal:  J Clin Exp Neuropsychol       Date:  2012-12-14       Impact factor: 2.475

5.  Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale.

Authors:  Sara Cross; Nur Önen; Amber Gase; Edgar Turner Overton; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-10       Impact factor: 4.147

6.  Effect of progression of disease on cognitive performance in HIV/AIDS.

Authors:  Francis Odiase; Olubunmi Ogunrin; Adesola Ogunniyi
Journal:  J Natl Med Assoc       Date:  2006-08       Impact factor: 1.798

7.  Both Financial and Cognitive Decline Predict Clinical Progression in MCI.

Authors:  Adam Gerstenecker; Kristen L Triebel; Roy Martin; Scott Snyder; Daniel C Marson
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Jan-Mar       Impact factor: 2.703

8.  Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China.

Authors:  Robert K Heaton; Lucette A Cysique; Hua Jin; Chuan Shi; Xin Yu; Scott Letendre; Donald R Franklin; Christopher Ake; Ofilio Vigil; J Hampton Atkinson; Thomas D Marcotte; Igor Grant; Zunyou Wu
Journal:  J Neurovirol       Date:  2008-11       Impact factor: 2.643

9.  "Frontal systems" behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency.

Authors:  María J Marquine; Jennifer E Iudicello; Erin E Morgan; Gregory G Brown; Scott L Letendre; Ronald J Ellis; Reena Deutsch; Steven Paul Woods; Igor Grant; Robert K Heaton
Journal:  Psychiatry Res       Date:  2013-11-13       Impact factor: 3.222

10.  Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.

Authors:  George K Hightower; Scott L Letendre; Mariana Cherner; Sarah A Gibson; Ronald J Ellis; Tanya J Wolfson; Anthony C Gamst; Caroline C Ignacio; Robert K Heaton; Igor Grant; Douglas D Richman; Davey M Smith
Journal:  Virology       Date:  2009-09-16       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.